#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Understanding mechanisms of viral strategy to evade from host antiviral responses is critical for elucidation of the pathogenesis of CSFV infection .
2-1	14-27	Understanding	_	_	_	_
2-2	28-38	mechanisms	abstract[2]	new[2]	_	_
2-3	39-41	of	abstract[2]	new[2]	_	_
2-4	42-47	viral	abstract[2]|organization|abstract[4]	new[2]|new|new[4]	coref|coref|coref|coref	9-7|10-62[88_4]|9-7|10-62[88_4]
2-5	48-56	strategy	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-6	57-59	to	_	_	_	_
2-7	60-65	evade	_	_	_	_
2-8	66-70	from	_	_	_	_
2-9	71-75	host	abstract[5]	new[5]	coref	9-13[65_5]
2-10	76-85	antiviral	abstract[5]	new[5]	_	_
2-11	86-95	responses	abstract[5]	new[5]	_	_
2-12	96-98	is	_	_	_	_
2-13	99-107	critical	_	_	_	_
2-14	108-111	for	_	_	_	_
2-15	112-123	elucidation	abstract[6]	new[6]	_	_
2-16	124-126	of	abstract[6]	new[6]	_	_
2-17	127-130	the	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-18	131-143	pathogenesis	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-19	144-146	of	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-20	147-151	CSFV	abstract[6]|abstract[7]|object|abstract[9]	new[6]|new[7]|new|new[9]	coref|coref|coref|coref	4-1|10-14[72_9]|4-1|10-14[72_9]
2-21	152-161	infection	abstract[6]|abstract[7]|abstract[9]	new[6]|new[7]|new[9]	_	_
2-22	162-163	.	_	_	_	_

#Text=Type I IFNs represent one of the first lines of defense of the innate immune system and are produced rapidly upon recognition of viral factors by PRRs .
3-1	164-168	Type	abstract	new	coref	4-10
3-2	169-170	I	person	acc	ana	4-11
3-3	171-175	IFNs	abstract	new	coref	4-12
3-4	176-185	represent	_	_	_	_
3-5	186-189	one	abstract[13]	new[13]	_	_
3-6	190-192	of	abstract[13]	new[13]	_	_
3-7	193-196	the	abstract[13]|object[14]	new[13]|new[14]	coref	17-1[145_14]
3-8	197-202	first	abstract[13]|object[14]	new[13]|new[14]	_	_
3-9	203-208	lines	abstract[13]|object[14]	new[13]|new[14]	_	_
3-10	209-211	of	abstract[13]|object[14]	new[13]|new[14]	_	_
3-11	212-219	defense	abstract[13]|object[14]|abstract[15]	new[13]|new[14]|new[15]	_	_
3-12	220-222	of	abstract[13]|object[14]|abstract[15]	new[13]|new[14]|new[15]	_	_
3-13	223-226	the	abstract[13]|object[14]|abstract[15]|abstract[16]	new[13]|new[14]|new[15]|new[16]	_	_
3-14	227-233	innate	abstract[13]|object[14]|abstract[15]|abstract[16]	new[13]|new[14]|new[15]|new[16]	_	_
3-15	234-240	immune	abstract[13]|object[14]|abstract[15]|abstract[16]	new[13]|new[14]|new[15]|new[16]	_	_
3-16	241-247	system	abstract[13]|object[14]|abstract[15]|abstract[16]	new[13]|new[14]|new[15]|new[16]	_	_
3-17	248-251	and	_	_	_	_
3-18	252-255	are	_	_	_	_
3-19	256-264	produced	_	_	_	_
3-20	265-272	rapidly	_	_	_	_
3-21	273-277	upon	_	_	_	_
3-22	278-289	recognition	event[17]	new[17]	_	_
3-23	290-292	of	event[17]	new[17]	_	_
3-24	293-298	viral	event[17]|abstract[18]	new[17]|new[18]	_	_
3-25	299-306	factors	event[17]|abstract[18]	new[17]|new[18]	_	_
3-26	307-309	by	event[17]|abstract[18]	new[17]|new[18]	_	_
3-27	310-314	PRRs	event[17]|abstract[18]|abstract	new[17]|new[18]|new	_	_
3-28	315-316	.	_	_	_	_

#Text=CSFV is known to interfere with the generation of type I IFNs by inducing proteasomal degradation of IRF3 .
4-1	317-321	CSFV	object	giv	coref	6-12
4-2	322-324	is	_	_	_	_
4-3	325-330	known	_	_	_	_
4-4	331-333	to	_	_	_	_
4-5	334-343	interfere	_	_	_	_
4-6	344-348	with	_	_	_	_
4-7	349-352	the	abstract[21]	new[21]	_	_
4-8	353-363	generation	abstract[21]	new[21]	_	_
4-9	364-366	of	abstract[21]	new[21]	_	_
4-10	367-371	type	abstract[21]|abstract	new[21]|giv	coref	5-1[28_0]
4-11	372-373	I	person	giv	ana	15-14
4-12	374-378	IFNs	abstract	giv	coref	7-15
4-13	379-381	by	_	_	_	_
4-14	382-390	inducing	_	_	_	_
4-15	391-402	proteasomal	animal|abstract[26]	new|new[26]	_	_
4-16	403-414	degradation	abstract[26]	new[26]	_	_
4-17	415-417	of	abstract[26]	new[26]	_	_
4-18	418-422	IRF3	abstract[26]|object	new[26]|new	coref	24-16
4-19	423-424	.	_	_	_	_

#Text=Type III IFNs play a critical role in antiviral innate immunity in mucosal epithelial cells .
5-1	425-429	Type	abstract[28]	giv[28]	coref	6-14[0_28]
5-2	430-433	III	abstract[28]	giv[28]	_	_
5-3	434-438	IFNs	abstract[28]	giv[28]	_	_
5-4	439-443	play	_	_	_	_
5-5	444-445	a	abstract[29]	new[29]	_	_
5-6	446-454	critical	abstract[29]	new[29]	_	_
5-7	455-459	role	abstract[29]	new[29]	_	_
5-8	460-462	in	abstract[29]	new[29]	_	_
5-9	463-472	antiviral	abstract[29]|abstract[30]	new[29]|new[30]	_	_
5-10	473-479	innate	abstract[29]|abstract[30]	new[29]|new[30]	_	_
5-11	480-488	immunity	abstract[29]|abstract[30]	new[29]|new[30]	_	_
5-12	489-491	in	abstract[29]|abstract[30]	new[29]|new[30]	_	_
5-13	492-499	mucosal	abstract[29]|abstract[30]|place[31]	new[29]|new[30]|new[31]	coref	10-46[84_31]
5-14	500-510	epithelial	abstract[29]|abstract[30]|place[31]	new[29]|new[30]|new[31]	_	_
5-15	511-516	cells	abstract[29]|abstract[30]|place[31]	new[29]|new[30]|new[31]	_	_
5-16	517-518	.	_	_	_	_

#Text=However , little information is available as to whether and how CSFV modulates type III IFN response .
6-1	519-526	However	_	_	_	_
6-2	527-528	,	_	_	_	_
6-3	529-535	little	abstract[32]	new[32]	_	_
6-4	536-547	information	abstract[32]	new[32]	_	_
6-5	548-550	is	_	_	_	_
6-6	551-560	available	_	_	_	_
6-7	561-563	as	_	_	_	_
6-8	564-566	to	_	_	_	_
6-9	567-574	whether	_	_	_	_
6-10	575-578	and	_	_	_	_
6-11	579-582	how	_	_	_	_
6-12	583-587	CSFV	object	giv	coref	7-10
6-13	588-597	modulates	_	_	_	_
6-14	598-602	type	abstract	giv	coref	7-12[41_0]
6-15	603-606	III	abstract[36]	new[36]	coref	10-25[76_36]
6-16	607-610	IFN	organization|abstract[36]	new|new[36]	coref	19-12
6-17	611-619	response	abstract[36]	new[36]	_	_
6-18	620-621	.	_	_	_	_

#Text=The present study demonstrates that the Npro protein of CSFV inhibited IRF1-mediated type III IFNs production by down-regulation of IRF1 expression and blockage of its nuclear translocation .
7-1	622-625	The	event[37]	new[37]	coref	8-30[58_37]
7-2	626-633	present	event[37]	new[37]	_	_
7-3	634-639	study	event[37]	new[37]	_	_
7-4	640-652	demonstrates	_	_	_	_
7-5	653-657	that	_	_	_	_
7-6	658-661	the	substance[39]	new[39]	ana	7-25[0_39]
7-7	662-666	Npro	object|substance[39]	new|new[39]	coref	18-29
7-8	667-674	protein	substance[39]	new[39]	_	_
7-9	675-677	of	substance[39]	new[39]	_	_
7-10	678-682	CSFV	substance[39]|object	new[39]|giv	coref	8-15[55_0]
7-11	683-692	inhibited	_	_	_	_
7-12	693-706	IRF1-mediated	abstract[41]	giv[41]	appos	7-14[43_41]
7-13	707-711	type	abstract[41]	giv[41]	_	_
7-14	712-715	III	abstract[43]	giv[43]	coref	9-12[63_43]
7-15	716-720	IFNs	object|abstract[43]	giv|giv[43]	coref	9-14
7-16	721-731	production	abstract[43]	giv[43]	_	_
7-17	732-734	by	_	_	_	_
7-18	735-750	down-regulation	abstract[44]	new[44]	_	_
7-19	751-753	of	abstract[44]	new[44]	_	_
7-20	754-758	IRF1	abstract[44]|abstract|abstract[46]	new[44]|new|new[46]	coref|coref	26-1|26-1
7-21	759-769	expression	abstract[44]|abstract[46]	new[44]|new[46]	_	_
7-22	770-773	and	abstract[44]	new[44]	_	_
7-23	774-782	blockage	abstract[44]|object[47]	new[44]|new[47]	_	_
7-24	783-785	of	abstract[44]|object[47]	new[44]|new[47]	_	_
7-25	786-789	its	abstract[44]|object[47]|substance|abstract[49]	new[44]|new[47]|giv|new[49]	coref|coref	18-28[166_0]|18-28[166_0]
7-26	790-797	nuclear	abstract[44]|object[47]|abstract[49]	new[44]|new[47]|new[49]	_	_
7-27	798-811	translocation	abstract[44]|object[47]|abstract[49]	new[44]|new[47]|new[49]	_	_
7-28	812-813	.	_	_	_	_

#Text=The Npro-deleted mutant showed similar growth kinetics to its parental strain , indicating that CSFV Npro does not alter the replication in cell culture , which is consistent with the previous study .
8-1	814-817	The	object[50]	new[50]	ana	8-9[0_50]
8-2	818-830	Npro-deleted	object[50]	new[50]	_	_
8-3	831-837	mutant	object[50]	new[50]	_	_
8-4	838-844	showed	_	_	_	_
8-5	845-852	similar	abstract[52]	new[52]	_	_
8-6	853-859	growth	abstract|abstract[52]	new|new[52]	_	_
8-7	860-868	kinetics	abstract[52]	new[52]	_	_
8-8	869-871	to	abstract[52]	new[52]	_	_
8-9	872-875	its	abstract[52]|object|object[54]	new[52]|giv|new[54]	coref|coref|coref|coref	18-4[156_0]|18-22[164_54]|18-4[156_0]|18-22[164_54]
8-10	876-884	parental	abstract[52]|object[54]	new[52]|new[54]	_	_
8-11	885-891	strain	abstract[52]|object[54]	new[52]|new[54]	_	_
8-12	892-893	,	_	_	_	_
8-13	894-904	indicating	_	_	_	_
8-14	905-909	that	_	_	_	_
8-15	910-914	CSFV	object[55]	giv[55]	coref	10-37[0_55]
8-16	915-919	Npro	object[55]	giv[55]	_	_
8-17	920-924	does	_	_	_	_
8-18	925-928	not	_	_	_	_
8-19	929-934	alter	_	_	_	_
8-20	935-938	the	abstract[56]	new[56]	_	_
8-21	939-950	replication	abstract[56]	new[56]	_	_
8-22	951-953	in	abstract[56]	new[56]	_	_
8-23	954-958	cell	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-24	959-966	culture	abstract[56]|abstract[57]	new[56]|new[57]	_	_
8-25	967-968	,	_	_	_	_
8-26	969-974	which	_	_	_	_
8-27	975-977	is	_	_	_	_
8-28	978-988	consistent	_	_	_	_
8-29	989-993	with	_	_	_	_
8-30	994-997	the	event[58]	giv[58]	coref	16-10[144_58]
8-31	998-1006	previous	event[58]	giv[58]	_	_
8-32	1007-1012	study	event[58]	giv[58]	_	_
8-33	1013-1014	.	_	_	_	_

#Text=Some viruses have evolved to encode viral antagonists for evasion of type III IFNs responses .
9-1	1015-1019	Some	animal[59]	new[59]	coref	26-8[237_59]
9-2	1020-1027	viruses	animal[59]	new[59]	_	_
9-3	1028-1032	have	_	_	_	_
9-4	1033-1040	evolved	_	_	_	_
9-5	1041-1043	to	_	_	_	_
9-6	1044-1050	encode	_	_	_	_
9-7	1051-1056	viral	organization|person[61]	giv|new[61]	coref|coref	28-11|28-11
9-8	1057-1068	antagonists	person[61]	new[61]	_	_
9-9	1069-1072	for	_	_	_	_
9-10	1073-1080	evasion	abstract[62]	new[62]	_	_
9-11	1081-1083	of	abstract[62]	new[62]	_	_
9-12	1084-1088	type	abstract[62]|abstract[63]	new[62]|giv[63]	coref	10-8[0_63]
9-13	1089-1092	III	abstract[62]|abstract[63]|abstract[65]	new[62]|giv[63]|giv[65]	_	_
9-14	1093-1097	IFNs	abstract[62]|abstract[63]|abstract|abstract[65]	new[62]|giv[63]|giv|giv[65]	coref	11-9
9-15	1098-1107	responses	abstract[62]|abstract[63]|abstract[65]	new[62]|giv[63]|giv[65]	_	_
9-16	1108-1109	.	_	_	_	_

#Text=Reid et al showed the induction of type III IFNs in pDCs upon BVDV infection , and type III IFNs contributed to suppression of cellular immune response during BVDV infection . Cai et al shows that CSFV induced the expression of type III IFNs in PK-15 cells , but with a limited level of increase , suggesting that CSFV might have a strategy to suppress expression of type III IFNs .
10-1	1110-1114	Reid	person	new	_	_
10-2	1115-1117	et	_	_	_	_
10-3	1118-1120	al	_	_	_	_
10-4	1121-1127	showed	_	_	_	_
10-5	1128-1131	the	abstract[67]	new[67]	_	_
10-6	1132-1141	induction	abstract[67]	new[67]	_	_
10-7	1142-1144	of	abstract[67]	new[67]	_	_
10-8	1145-1149	type	abstract[67]|abstract	new[67]|giv	appos	10-9[69_0]
10-9	1150-1153	III	abstract[69]	giv[69]	coref	10-18[73_69]
10-10	1154-1158	IFNs	abstract[69]	giv[69]	_	_
10-11	1159-1161	in	_	_	_	_
10-12	1162-1166	pDCs	place[70]	new[70]	_	_
10-13	1167-1171	upon	place[70]	new[70]	_	_
10-14	1172-1176	BVDV	place[70]|object|abstract[72]	new[70]|new|giv[72]	coref|coref	10-29[77_72]|10-29[77_72]
10-15	1177-1186	infection	place[70]|abstract[72]	new[70]|giv[72]	_	_
10-16	1187-1188	,	_	_	_	_
10-17	1189-1192	and	_	_	_	_
10-18	1193-1197	type	abstract[73]	giv[73]	coref	10-42[0_73]
10-19	1198-1201	III	abstract[73]	giv[73]	_	_
10-20	1202-1206	IFNs	abstract[73]	giv[73]	_	_
10-21	1207-1218	contributed	_	_	_	_
10-22	1219-1221	to	_	_	_	_
10-23	1222-1233	suppression	abstract[74]	new[74]	_	_
10-24	1234-1236	of	abstract[74]	new[74]	_	_
10-25	1237-1245	cellular	abstract[74]|abstract[76]	new[74]|giv[76]	_	_
10-26	1246-1252	immune	abstract[74]|abstract|abstract[76]	new[74]|new|giv[76]	_	_
10-27	1253-1261	response	abstract[74]|abstract[76]	new[74]|giv[76]	_	_
10-28	1262-1268	during	abstract[74]|abstract[76]	new[74]|giv[76]	_	_
10-29	1269-1273	BVDV	abstract[74]|abstract[76]|abstract[77]	new[74]|giv[76]|giv[77]	coref	11-12[99_77]
10-30	1274-1283	infection	abstract[74]|abstract[76]|abstract[77]	new[74]|giv[76]|giv[77]	_	_
10-31	1284-1285	.	_	_	_	_
10-32	1286-1289	Cai	person	new	coref	11-38
10-33	1290-1292	et	_	_	_	_
10-34	1293-1295	al	_	_	_	_
10-35	1296-1301	shows	_	_	_	_
10-36	1302-1306	that	_	_	_	_
10-37	1307-1311	CSFV	object	giv	coref	10-59
10-38	1312-1319	induced	_	_	_	_
10-39	1320-1323	the	abstract[80]	new[80]	_	_
10-40	1324-1334	expression	abstract[80]	new[80]	_	_
10-41	1335-1337	of	abstract[80]	new[80]	_	_
10-42	1338-1342	type	abstract[80]|abstract	new[80]|giv	appos	10-43[82_0]
10-43	1343-1346	III	abstract[82]	giv[82]	coref	10-68[0_82]
10-44	1347-1351	IFNs	abstract[82]	giv[82]	_	_
10-45	1352-1354	in	_	_	_	_
10-46	1355-1360	PK-15	time|place[84]	new|giv[84]	coref|coref	11-15[101_84]|11-15[101_84]
10-47	1361-1366	cells	place[84]	giv[84]	_	_
10-48	1367-1368	,	_	_	_	_
10-49	1369-1372	but	_	_	_	_
10-50	1373-1377	with	_	_	_	_
10-51	1378-1379	a	abstract[85]	new[85]	coref	11-19[103_85]
10-52	1380-1387	limited	abstract[85]	new[85]	_	_
10-53	1388-1393	level	abstract[85]	new[85]	_	_
10-54	1394-1396	of	abstract[85]	new[85]	_	_
10-55	1397-1405	increase	abstract[85]|abstract	new[85]|new	_	_
10-56	1406-1407	,	_	_	_	_
10-57	1408-1418	suggesting	_	_	_	_
10-58	1419-1423	that	_	_	_	_
10-59	1424-1428	CSFV	object	giv	coref	13-2
10-60	1429-1434	might	_	_	_	_
10-61	1435-1439	have	_	_	_	_
10-62	1440-1441	a	abstract[88]	giv[88]	_	_
10-63	1442-1450	strategy	abstract[88]	giv[88]	_	_
10-64	1451-1453	to	_	_	_	_
10-65	1454-1462	suppress	_	_	_	_
10-66	1463-1473	expression	abstract[89]	new[89]	coref	18-35[167_89]
10-67	1474-1476	of	abstract[89]	new[89]	_	_
10-68	1477-1481	type	abstract[89]|abstract	new[89]|giv	appos	10-69[91_0]
10-69	1482-1485	III	abstract[91]	giv[91]	coref	11-7[0_91]
10-70	1486-1490	IFNs	abstract[91]	giv[91]	_	_
10-71	1491-1492	.	_	_	_	_

#Text=We also found limited up-regulation of type III IFNs transcription upon wtCSFV infection in IPEC-J2 cells , though the transcription level peaked at 24 hpi and decreased thereafter , which is different from the results shown by Cai et al that the mRNA level of IFN-λ1 and IFN-λ3 induced by wtCSFV peaked at 36 and 48 hpi , respectively .
11-1	1493-1495	We	person	acc	ana	12-1
11-2	1496-1500	also	_	_	_	_
11-3	1501-1506	found	_	_	_	_
11-4	1507-1514	limited	abstract[93]	new[93]	_	_
11-5	1515-1528	up-regulation	abstract[93]	new[93]	_	_
11-6	1529-1531	of	abstract[93]	new[93]	_	_
11-7	1532-1536	type	abstract[93]|abstract|abstract[95]	new[93]|giv|new[95]	coref|coref|coref|coref	15-6|19-9[172_95]|15-6|19-9[172_95]
11-8	1537-1540	III	abstract[93]|abstract[95]|abstract[97]	new[93]|new[95]|new[97]	coref	11-20[0_97]
11-9	1541-1545	IFNs	abstract[93]|abstract[95]|abstract|abstract[97]	new[93]|new[95]|giv|new[97]	coref	15-15
11-10	1546-1559	transcription	abstract[93]|abstract[95]|abstract[97]	new[93]|new[95]|new[97]	_	_
11-11	1560-1564	upon	abstract[93]|abstract[95]|abstract[97]	new[93]|new[95]|new[97]	_	_
11-12	1565-1571	wtCSFV	abstract[93]|abstract[95]|abstract[97]|object|abstract[99]	new[93]|new[95]|new[97]|new|giv[99]	coref|coref|coref|coref	11-51|14-20[0_99]|11-51|14-20[0_99]
11-13	1572-1581	infection	abstract[93]|abstract[95]|abstract[97]|abstract[99]	new[93]|new[95]|new[97]|giv[99]	_	_
11-14	1582-1584	in	abstract[93]|abstract[95]|abstract[97]|abstract[99]	new[93]|new[95]|new[97]|giv[99]	_	_
11-15	1585-1592	IPEC-J2	abstract[93]|abstract[95]|abstract[97]|abstract[99]|substance|place[101]	new[93]|new[95]|new[97]|giv[99]|new|giv[101]	coref|coref|coref|coref	14-2|14-7[127_101]|14-2|14-7[127_101]
11-16	1593-1598	cells	abstract[93]|abstract[95]|abstract[97]|abstract[99]|place[101]	new[93]|new[95]|new[97]|giv[99]|giv[101]	_	_
11-17	1599-1600	,	_	_	_	_
11-18	1601-1607	though	_	_	_	_
11-19	1608-1611	the	abstract[103]	giv[103]	_	_
11-20	1612-1625	transcription	abstract|abstract[103]	giv|giv[103]	coref	18-8[157_0]
11-21	1626-1631	level	abstract[103]	giv[103]	_	_
11-22	1632-1638	peaked	_	_	_	_
11-23	1639-1641	at	_	_	_	_
11-24	1642-1644	24	quantity[104]	new[104]	_	_
11-25	1645-1648	hpi	quantity[104]	new[104]	_	_
11-26	1649-1652	and	_	_	_	_
11-27	1653-1662	decreased	_	_	_	_
11-28	1663-1673	thereafter	_	_	_	_
11-29	1674-1675	,	_	_	_	_
11-30	1676-1681	which	_	_	_	_
11-31	1682-1684	is	_	_	_	_
11-32	1685-1694	different	_	_	_	_
11-33	1695-1699	from	_	_	_	_
11-34	1700-1703	the	abstract[105]	new[105]	coref	23-1[211_105]
11-35	1704-1711	results	abstract[105]	new[105]	_	_
11-36	1712-1717	shown	_	_	_	_
11-37	1718-1720	by	_	_	_	_
11-38	1721-1724	Cai	person	giv	_	_
11-39	1725-1727	et	_	_	_	_
11-40	1728-1730	al	_	_	_	_
11-41	1731-1735	that	_	_	_	_
11-42	1736-1739	the	abstract[108]	new[108]	_	_
11-43	1740-1744	mRNA	place|abstract[108]	new|new[108]	coref	21-13
11-44	1745-1750	level	abstract[108]	new[108]	_	_
11-45	1751-1753	of	abstract[108]	new[108]	_	_
11-46	1754-1760	IFN-λ1	abstract[108]|abstract	new[108]|new	_	_
11-47	1761-1764	and	abstract[108]	new[108]	_	_
11-48	1765-1771	IFN-λ3	abstract[108]|abstract	new[108]|new	coref	22-16
11-49	1772-1779	induced	_	_	_	_
11-50	1780-1782	by	_	_	_	_
11-51	1783-1789	wtCSFV	abstract	giv	coref	20-4
11-52	1790-1796	peaked	_	_	_	_
11-53	1797-1799	at	_	_	_	_
11-54	1800-1802	36	quantity	new	_	_
11-55	1803-1806	and	_	_	_	_
11-56	1807-1809	48	quantity[113]	new[113]	coref	18-19[162_113]
11-57	1810-1813	hpi	quantity[113]	new[113]	_	_
11-58	1814-1815	,	_	_	_	_
11-59	1816-1828	respectively	_	_	_	_
11-60	1829-1830	.	_	_	_	_

#Text=We speculate that the difference might be due to different cell types used .
12-1	1831-1833	We	person	giv	ana	18-1
12-2	1834-1843	speculate	_	_	_	_
12-3	1844-1848	that	_	_	_	_
12-4	1849-1852	the	abstract[115]	new[115]	_	_
12-5	1853-1863	difference	abstract[115]	new[115]	_	_
12-6	1864-1869	might	_	_	_	_
12-7	1870-1872	be	_	_	_	_
12-8	1873-1876	due	_	_	_	_
12-9	1877-1879	to	_	_	_	_
12-10	1880-1889	different	abstract[117]	new[117]	_	_
12-11	1890-1894	cell	object|abstract[117]	new|new[117]	coref	13-8
12-12	1895-1900	types	abstract[117]	new[117]	_	_
12-13	1901-1905	used	_	_	_	_
12-14	1906-1907	.	_	_	_	_

#Text=Because CSFV causes enteric pathologies , a cell line from the intestines could be a good choice .
13-1	1908-1915	Because	_	_	_	_
13-2	1916-1920	CSFV	substance	giv	coref	17-24
13-3	1921-1927	causes	_	_	_	_
13-4	1928-1935	enteric	abstract[119]	new[119]	_	_
13-5	1936-1947	pathologies	abstract[119]	new[119]	_	_
13-6	1948-1949	,	_	_	_	_
13-7	1950-1951	a	abstract[121]	new[121]	coref	13-15[123_121]
13-8	1952-1956	cell	object|abstract[121]	giv|new[121]	coref	14-3
13-9	1957-1961	line	abstract[121]	new[121]	_	_
13-10	1962-1966	from	abstract[121]	new[121]	_	_
13-11	1967-1970	the	abstract[121]|place[122]	new[121]|new[122]	_	_
13-12	1971-1981	intestines	abstract[121]|place[122]	new[121]|new[122]	_	_
13-13	1982-1987	could	_	_	_	_
13-14	1988-1990	be	_	_	_	_
13-15	1991-1992	a	abstract[123]	giv[123]	coref	14-1[126_123]
13-16	1993-1997	good	abstract[123]	giv[123]	_	_
13-17	1998-2004	choice	abstract[123]	giv[123]	_	_
13-18	2005-2006	.	_	_	_	_

#Text=The IPEC-J2 cell line was from non-transformed cells collected from the jejunum of a neonatal piglet and suitable for infection studies for enteropathogens .
14-1	2007-2010	The	abstract[126]	giv[126]	coref	16-3[143_126]
14-2	2011-2018	IPEC-J2	time|abstract[126]	giv|giv[126]	coref	15-1
14-3	2019-2023	cell	object|abstract[126]	giv|giv[126]	coref	16-5
14-4	2024-2028	line	abstract[126]	giv[126]	_	_
14-5	2029-2032	was	_	_	_	_
14-6	2033-2037	from	_	_	_	_
14-7	2038-2053	non-transformed	place[127]	giv[127]	coref	18-14[160_127]
14-8	2054-2059	cells	place[127]	giv[127]	_	_
14-9	2060-2069	collected	_	_	_	_
14-10	2070-2074	from	_	_	_	_
14-11	2075-2078	the	object[128]	new[128]	_	_
14-12	2079-2086	jejunum	object[128]	new[128]	_	_
14-13	2087-2089	of	object[128]	new[128]	_	_
14-14	2090-2091	a	object[128]|animal[129]	new[128]|new[129]	_	_
14-15	2092-2100	neonatal	object[128]|animal[129]	new[128]|new[129]	_	_
14-16	2101-2107	piglet	object[128]|animal[129]	new[128]|new[129]	_	_
14-17	2108-2111	and	object[128]	new[128]	_	_
14-18	2112-2120	suitable	object[128]	new[128]	_	_
14-19	2121-2124	for	_	_	_	_
14-20	2125-2134	infection	abstract|event[131]	giv|new[131]	coref|coref	22-1[200_0]|22-1[200_0]
14-21	2135-2142	studies	event[131]	new[131]	_	_
14-22	2143-2146	for	_	_	_	_
14-23	2147-2162	enteropathogens	abstract	new	_	_
14-24	2163-2164	.	_	_	_	_

#Text=IPEC-J2 exhibited robust expression of type III IFNs with a relatively lower type I IFNs response .
15-1	2165-2172	IPEC-J2	organization	giv	coref	16-4
15-2	2173-2182	exhibited	_	_	_	_
15-3	2183-2189	robust	abstract[134]	new[134]	_	_
15-4	2190-2200	expression	abstract[134]	new[134]	_	_
15-5	2201-2203	of	abstract[134]	new[134]	_	_
15-6	2204-2208	type	abstract[134]|abstract	new[134]|giv	coref	15-7[136_0]
15-7	2209-2212	III	abstract[136]	giv[136]	coref	15-10[137_136]
15-8	2213-2217	IFNs	abstract[136]	giv[136]	_	_
15-9	2218-2222	with	_	_	_	_
15-10	2223-2224	a	abstract[137]	giv[137]	appos	15-15[140_137]
15-11	2225-2235	relatively	abstract[137]	giv[137]	_	_
15-12	2236-2241	lower	abstract[137]	giv[137]	_	_
15-13	2242-2246	type	abstract[137]	giv[137]	_	_
15-14	2247-2248	I	person	giv	ana	19-11
15-15	2249-2253	IFNs	organization|abstract[140]	giv|giv[140]	coref|coref|coref|coref	17-26[0_140]|18-12|17-26[0_140]|18-12
15-16	2254-2262	response	abstract[140]	giv[140]	_	_
15-17	2263-2264	.	_	_	_	_

#Text=Thus , the IPEC-J2 cell line was chosen in this study .
16-1	2265-2269	Thus	_	_	_	_
16-2	2270-2271	,	_	_	_	_
16-3	2272-2275	the	abstract[143]	giv[143]	_	_
16-4	2276-2283	IPEC-J2	time|abstract[143]	giv|giv[143]	coref	18-14
16-5	2284-2288	cell	object|abstract[143]	giv|giv[143]	_	_
16-6	2289-2293	line	abstract[143]	giv[143]	_	_
16-7	2294-2297	was	_	_	_	_
16-8	2298-2304	chosen	_	_	_	_
16-9	2305-2307	in	_	_	_	_
16-10	2308-2312	this	event[144]	giv[144]	_	_
16-11	2313-2318	study	event[144]	giv[144]	_	_
16-12	2319-2320	.	_	_	_	_

#Text=Cell lines or primary cultures from other intestinal areas or from adult pigs could be approached for further investigation of the interactions between CSFV and type III IFNs .
17-1	2321-2325	Cell	object[145]	giv[145]	_	_
17-2	2326-2331	lines	object[145]	giv[145]	_	_
17-3	2332-2334	or	object[145]	giv[145]	_	_
17-4	2335-2342	primary	object[145]|abstract[146]	giv[145]|new[146]	_	_
17-5	2343-2351	cultures	object[145]|abstract[146]	giv[145]|new[146]	_	_
17-6	2352-2356	from	object[145]|abstract[146]	giv[145]|new[146]	_	_
17-7	2357-2362	other	object[145]|abstract[146]|place[147]	giv[145]|new[146]|new[147]	_	_
17-8	2363-2373	intestinal	object[145]|abstract[146]|place[147]	giv[145]|new[146]|new[147]	_	_
17-9	2374-2379	areas	object[145]|abstract[146]|place[147]	giv[145]|new[146]|new[147]	_	_
17-10	2380-2382	or	_	_	_	_
17-11	2383-2387	from	_	_	_	_
17-12	2388-2393	adult	animal[148]	new[148]	_	_
17-13	2394-2398	pigs	animal[148]	new[148]	_	_
17-14	2399-2404	could	_	_	_	_
17-15	2405-2407	be	_	_	_	_
17-16	2408-2418	approached	_	_	_	_
17-17	2419-2422	for	_	_	_	_
17-18	2423-2430	further	abstract[149]	new[149]	_	_
17-19	2431-2444	investigation	abstract[149]	new[149]	_	_
17-20	2445-2447	of	abstract[149]	new[149]	_	_
17-21	2448-2451	the	abstract[149]|abstract[150]	new[149]|new[150]	_	_
17-22	2452-2464	interactions	abstract[149]|abstract[150]	new[149]|new[150]	_	_
17-23	2465-2472	between	abstract[149]|abstract[150]	new[149]|new[150]	_	_
17-24	2473-2477	CSFV	abstract[149]|abstract[150]|object	new[149]|new[150]|giv	coref	19-2[170_0]
17-25	2478-2481	and	abstract[149]|abstract[150]	new[149]|new[150]	_	_
17-26	2482-2486	type	abstract[149]|abstract[150]|abstract	new[149]|new[150]|giv	coref	17-27[153_0]
17-27	2487-2490	III	abstract[149]|abstract[150]|abstract[153]	new[149]|new[150]|giv[153]	coref	18-37[0_153]
17-28	2491-2495	IFNs	abstract[149]|abstract[150]|abstract[153]	new[149]|new[150]|giv[153]	_	_
17-29	2496-2497	.	_	_	_	_

#Text=We found that the ∆Npro mutant induced significantly higher transcription of IFNs in IPEC-J2 cells from 24 to 48 hpi than its parental strain , suggesting that the Npro protein might be antagonistic to expression of type III IFNs .
18-1	2498-2500	We	person	giv	ana	19-15
18-2	2501-2506	found	_	_	_	_
18-3	2507-2511	that	_	_	_	_
18-4	2512-2515	the	object[156]	giv[156]	_	_
18-5	2516-2521	∆Npro	abstract|object[156]	new|giv[156]	_	_
18-6	2522-2528	mutant	object[156]	giv[156]	_	_
18-7	2529-2536	induced	_	_	_	_
18-8	2537-2550	significantly	abstract[157]	giv[157]	ana	18-22[0_157]
18-9	2551-2557	higher	abstract[157]	giv[157]	_	_
18-10	2558-2571	transcription	abstract[157]	giv[157]	_	_
18-11	2572-2574	of	abstract[157]	giv[157]	_	_
18-12	2575-2579	IFNs	abstract[157]|abstract	giv[157]|giv	coref	23-13
18-13	2580-2582	in	abstract[157]	giv[157]	_	_
18-14	2583-2590	IPEC-J2	abstract[157]|substance|place[160]	giv[157]|giv|giv[160]	coref|coref|coref|coref	20-16|20-16[188_160]|20-16|20-16[188_160]
18-15	2591-2596	cells	abstract[157]|place[160]	giv[157]|giv[160]	_	_
18-16	2597-2601	from	abstract[157]|place[160]	giv[157]|giv[160]	_	_
18-17	2602-2604	24	abstract[157]|place[160]|quantity	giv[157]|giv[160]|new	_	_
18-18	2605-2607	to	_	_	_	_
18-19	2608-2610	48	quantity[162]	giv[162]	_	_
18-20	2611-2614	hpi	quantity[162]	giv[162]	_	_
18-21	2615-2619	than	quantity[162]	giv[162]	_	_
18-22	2620-2623	its	quantity[162]|abstract|object[164]	giv[162]|giv|giv[164]	_	_
18-23	2624-2632	parental	quantity[162]|object[164]	giv[162]|giv[164]	_	_
18-24	2633-2639	strain	quantity[162]|object[164]	giv[162]|giv[164]	_	_
18-25	2640-2641	,	_	_	_	_
18-26	2642-2652	suggesting	_	_	_	_
18-27	2653-2657	that	_	_	_	_
18-28	2658-2661	the	substance[166]	giv[166]	_	_
18-29	2662-2666	Npro	object|substance[166]	giv|giv[166]	coref	19-18
18-30	2667-2674	protein	substance[166]	giv[166]	_	_
18-31	2675-2680	might	_	_	_	_
18-32	2681-2683	be	_	_	_	_
18-33	2684-2696	antagonistic	_	_	_	_
18-34	2697-2699	to	_	_	_	_
18-35	2700-2710	expression	abstract[167]	giv[167]	coref	32-31[295_167]
18-36	2711-2713	of	abstract[167]	giv[167]	_	_
18-37	2714-2718	type	abstract[167]|abstract	giv[167]|giv	coref	18-38[169_0]
18-38	2719-2722	III	abstract[169]	giv[169]	coref	19-9[171_169]
18-39	2723-2727	IFNs	abstract[169]	giv[169]	_	_
18-40	2728-2729	.	_	_	_	_

#Text=Because CSFV Npro has been found to subvert the type I IFN response , we speculated if Npro might have similar effect on type III IFNs .
19-1	2730-2737	Because	_	_	_	_
19-2	2738-2742	CSFV	abstract[170]	giv[170]	coref	23-5[0_170]
19-3	2743-2747	Npro	abstract[170]	giv[170]	_	_
19-4	2748-2751	has	_	_	_	_
19-5	2752-2756	been	_	_	_	_
19-6	2757-2762	found	_	_	_	_
19-7	2763-2765	to	_	_	_	_
19-8	2766-2773	subvert	_	_	_	_
19-9	2774-2777	the	abstract[171]|abstract[172]	giv[171]|giv[172]	coref|coref	19-12[175_171]|19-12[175_171]
19-10	2778-2782	type	abstract[171]|abstract[172]	giv[171]|giv[172]	_	_
19-11	2783-2784	I	abstract[172]|person	giv[172]|giv	ana	24-12
19-12	2785-2788	IFN	abstract[172]|organization|abstract[175]	giv[172]|giv|giv[175]	coref|coref	19-24[0_175]|19-24[0_175]
19-13	2789-2797	response	abstract[172]|abstract[175]	giv[172]|giv[175]	_	_
19-14	2798-2799	,	_	_	_	_
19-15	2800-2802	we	person	giv	ana	20-1
19-16	2803-2813	speculated	_	_	_	_
19-17	2814-2816	if	_	_	_	_
19-18	2817-2821	Npro	substance	giv	coref	20-19
19-19	2822-2827	might	_	_	_	_
19-20	2828-2832	have	_	_	_	_
19-21	2833-2840	similar	abstract[178]	new[178]	coref	20-22[191_178]
19-22	2841-2847	effect	abstract[178]	new[178]	_	_
19-23	2848-2850	on	abstract[178]	new[178]	_	_
19-24	2851-2855	type	abstract[178]|abstract	new[178]|giv	coref	19-25[180_0]
19-25	2856-2859	III	abstract[180]	giv[180]	coref	20-13[186_180]
19-26	2860-2864	IFNs	abstract[180]	giv[180]	_	_
19-27	2865-2866	.	_	_	_	_

#Text=We showed that wtCSFV strongly inhibited expression of poly(I : C)-induced type III IFNs in IPEC-J2 cells and Npro deletion abolished such an inhibitory effect .
20-1	2867-2869	We	person	giv	ana	21-1
20-2	2870-2876	showed	_	_	_	_
20-3	2877-2881	that	_	_	_	_
20-4	2882-2888	wtCSFV	abstract	giv	coref	22-4
20-5	2889-2897	strongly	_	_	_	_
20-6	2898-2907	inhibited	_	_	_	_
20-7	2908-2918	expression	abstract[183]	new[183]	coref	23-12[217_183]
20-8	2919-2921	of	abstract[183]	new[183]	_	_
20-9	2922-2928	poly(I	abstract[183]|abstract	new[183]|new	appos	20-11[185_0]
20-10	2929-2930	:	_	_	_	_
20-11	2931-2941	C)-induced	abstract[185]	giv[185]	coref	21-16[198_185]
20-12	2942-2946	type	abstract[185]	giv[185]	_	_
20-13	2947-2950	III	abstract[186]	giv[186]	coref	21-17[199_186]
20-14	2951-2955	IFNs	abstract[186]	giv[186]	_	_
20-15	2956-2958	in	_	_	_	_
20-16	2959-2966	IPEC-J2	substance|place[188]	giv|giv[188]	coref|coref	22-23|22-23
20-17	2967-2972	cells	place[188]	giv[188]	_	_
20-18	2973-2976	and	place[188]	giv[188]	_	_
20-19	2977-2981	Npro	place[188]|person|event[190]	giv[188]|giv|new[190]	coref|coref	21-5|21-5
20-20	2982-2990	deletion	place[188]|event[190]	giv[188]|new[190]	_	_
20-21	2991-3000	abolished	_	_	_	_
20-22	3001-3005	such	abstract[191]	giv[191]	_	_
20-23	3006-3008	an	abstract[191]	giv[191]	_	_
20-24	3009-3019	inhibitory	abstract[191]	giv[191]	_	_
20-25	3020-3026	effect	abstract[191]	giv[191]	_	_
20-26	3027-3028	.	_	_	_	_

#Text=We further showed that Npro over-expression led to a marked reduction of mRNA transcripts of type III IFNs .
21-1	3029-3031	We	person	giv	ana	31-13
21-2	3032-3039	further	_	_	_	_
21-3	3040-3046	showed	_	_	_	_
21-4	3047-3051	that	_	_	_	_
21-5	3052-3056	Npro	person|abstract[194]	giv|new[194]	coref|coref|coref|coref	22-6[202_194]|22-8|22-6[202_194]|22-8
21-6	3057-3072	over-expression	abstract[194]	new[194]	_	_
21-7	3073-3076	led	_	_	_	_
21-8	3077-3079	to	_	_	_	_
21-9	3080-3081	a	abstract[195]	new[195]	_	_
21-10	3082-3088	marked	abstract[195]	new[195]	_	_
21-11	3089-3098	reduction	abstract[195]	new[195]	_	_
21-12	3099-3101	of	abstract[195]	new[195]	_	_
21-13	3102-3106	mRNA	abstract[195]|object|abstract[197]	new[195]|giv|new[197]	_	_
21-14	3107-3118	transcripts	abstract[195]|abstract[197]	new[195]|new[197]	_	_
21-15	3119-3121	of	abstract[195]|abstract[197]	new[195]|new[197]	_	_
21-16	3122-3126	type	abstract[195]|abstract[197]|abstract[198]	new[195]|new[197]|giv[198]	coref	22-20[0_198]
21-17	3127-3130	III	abstract[195]|abstract[197]|abstract[198]|abstract[199]	new[195]|new[197]|giv[198]|giv[199]	coref	24-4[223_199]
21-18	3131-3135	IFNs	abstract[195]|abstract[197]|abstract[198]|abstract[199]	new[195]|new[197]|giv[198]|giv[199]	_	_
21-19	3136-3137	.	_	_	_	_

#Text=Either infection with wtCSFV or over-expression of Npro also resulted in significant reduction of the IFN-λ3 promoter activity of poly(I : C)-treated IPEC-J2 cells .
22-1	3138-3144	Either	abstract[200]	giv[200]	coref	28-11[256_200]
22-2	3145-3154	infection	abstract[200]	giv[200]	_	_
22-3	3155-3159	with	abstract[200]	giv[200]	_	_
22-4	3160-3166	wtCSFV	abstract[200]|abstract	giv[200]|giv	_	_
22-5	3167-3169	or	abstract[200]	giv[200]	_	_
22-6	3170-3185	over-expression	abstract[200]|abstract[202]	giv[200]|giv[202]	_	_
22-7	3186-3188	of	abstract[200]|abstract[202]	giv[200]|giv[202]	_	_
22-8	3189-3193	Npro	abstract[200]|abstract[202]|organization	giv[200]|giv[202]|giv	coref	23-7[214_0]
22-9	3194-3198	also	_	_	_	_
22-10	3199-3207	resulted	_	_	_	_
22-11	3208-3210	in	_	_	_	_
22-12	3211-3222	significant	abstract[204]	new[204]	_	_
22-13	3223-3232	reduction	abstract[204]	new[204]	_	_
22-14	3233-3235	of	abstract[204]	new[204]	_	_
22-15	3236-3239	the	abstract[204]|abstract[207]	new[204]|new[207]	coref	32-15[291_207]
22-16	3240-3246	IFN-λ3	abstract[204]|place|abstract[207]	new[204]|giv|new[207]	coref	32-15
22-17	3247-3255	promoter	abstract[204]|person|abstract[207]	new[204]|new|new[207]	coref	32-16
22-18	3256-3264	activity	abstract[204]|abstract[207]	new[204]|new[207]	_	_
22-19	3265-3267	of	abstract[204]|abstract[207]	new[204]|new[207]	_	_
22-20	3268-3274	poly(I	abstract[204]|abstract[207]|abstract	new[204]|new[207]|giv	appos	22-22[210_0]
22-21	3275-3276	:	_	_	_	_
22-22	3277-3287	C)-treated	abstract[210]	giv[210]	coref	23-11[0_210]
22-23	3288-3295	IPEC-J2	substance|abstract[210]	giv|giv[210]	coref	31-27
22-24	3296-3301	cells	abstract[210]	giv[210]	_	_
22-25	3302-3303	.	_	_	_	_

#Text=These results demonstrate that CSFV employs its Npro to inhibit type III IFNs expression probably by targeting the regulatory elements involved in transcription of IFN-λs .
23-1	3304-3309	These	abstract[211]	giv[211]	_	_
23-2	3310-3317	results	abstract[211]	giv[211]	_	_
23-3	3318-3329	demonstrate	_	_	_	_
23-4	3330-3334	that	_	_	_	_
23-5	3335-3339	CSFV	object	giv	ana	23-7
23-6	3340-3347	employs	_	_	_	_
23-7	3348-3351	its	object|abstract[214]	giv|giv[214]	_	_
23-8	3352-3356	Npro	abstract[214]	giv[214]	_	_
23-9	3357-3359	to	_	_	_	_
23-10	3360-3367	inhibit	_	_	_	_
23-11	3368-3372	type	abstract	giv	coref	24-3
23-12	3373-3376	III	abstract[217]	giv[217]	_	_
23-13	3377-3381	IFNs	person|abstract[217]	giv|giv[217]	coref	24-13
23-14	3382-3392	expression	abstract[217]	giv[217]	_	_
23-15	3393-3401	probably	abstract[217]	giv[217]	_	_
23-16	3402-3404	by	_	_	_	_
23-17	3405-3414	targeting	_	_	_	_
23-18	3415-3418	the	abstract[218]	new[218]	_	_
23-19	3419-3429	regulatory	abstract[218]	new[218]	_	_
23-20	3430-3438	elements	abstract[218]	new[218]	_	_
23-21	3439-3447	involved	_	_	_	_
23-22	3448-3450	in	_	_	_	_
23-23	3451-3464	transcription	abstract[219]	new[219]	_	_
23-24	3465-3467	of	abstract[219]	new[219]	_	_
23-25	3468-3474	IFN-λs	abstract[219]|abstract	new[219]|new	coref	28-7
23-26	3475-3476	.	_	_	_	_

#Text=Activation of type III IFNs , as the case with type I IFNs , requires IRF3 , IRF7 and NF-κB .
24-1	3477-3487	Activation	abstract[221]	new[221]	_	_
24-2	3488-3490	of	abstract[221]	new[221]	_	_
24-3	3491-3495	type	abstract[221]|abstract	new[221]|giv	coref	24-11
24-4	3496-3499	III	abstract[221]|abstract[223]	new[221]|giv[223]	coref	25-6[232_223]
24-5	3500-3504	IFNs	abstract[221]|abstract[223]	new[221]|giv[223]	_	_
24-6	3505-3506	,	abstract[221]	new[221]	_	_
24-7	3507-3509	as	abstract[221]	new[221]	_	_
24-8	3510-3513	the	abstract[221]	new[221]	_	_
24-9	3514-3518	case	abstract[221]	new[221]	_	_
24-10	3519-3523	with	abstract[221]	new[221]	_	_
24-11	3524-3528	type	abstract[221]|abstract	new[221]|giv	coref	25-5
24-12	3529-3530	I	person	giv	ana	27-20
24-13	3531-3535	IFNs	abstract	giv	coref	27-21
24-14	3536-3537	,	_	_	_	_
24-15	3538-3546	requires	_	_	_	_
24-16	3547-3551	IRF3	abstract	giv	appos	24-18
24-17	3552-3553	,	_	_	_	_
24-18	3554-3558	IRF7	abstract	giv	_	_
24-19	3559-3562	and	_	_	_	_
24-20	3563-3568	NF-κB	abstract	new	_	_
24-21	3569-3570	.	_	_	_	_

#Text=However , expression of type III IFNs does not need all components of the enhanceosome .
25-1	3571-3578	However	_	_	_	_
25-2	3579-3580	,	_	_	_	_
25-3	3581-3591	expression	abstract[230]	new[230]	coref	27-31[250_230]
25-4	3592-3594	of	abstract[230]	new[230]	_	_
25-5	3595-3599	type	abstract[230]|abstract	new[230]|giv	coref	27-19
25-6	3600-3603	III	abstract[230]|abstract[232]	new[230]|giv[232]	coref	27-17[243_232]
25-7	3604-3608	IFNs	abstract[230]|abstract[232]	new[230]|giv[232]	_	_
25-8	3609-3613	does	_	_	_	_
25-9	3614-3617	not	_	_	_	_
25-10	3618-3622	need	_	_	_	_
25-11	3623-3626	all	abstract[233]	new[233]	_	_
25-12	3627-3637	components	abstract[233]	new[233]	_	_
25-13	3638-3640	of	abstract[233]	new[233]	_	_
25-14	3641-3644	the	abstract[233]|abstract[234]	new[233]|new[234]	_	_
25-15	3645-3657	enhanceosome	abstract[233]|abstract[234]	new[233]|new[234]	_	_
25-16	3658-3659	.	_	_	_	_

#Text=IRF1 is a predominant antiviral molecule against many viruses .
26-1	3660-3664	IRF1	substance	giv	coref	26-3[236_0]
26-2	3665-3667	is	_	_	_	_
26-3	3668-3669	a	substance[236]	giv[236]	ana	27-1[0_236]
26-4	3670-3681	predominant	substance[236]	giv[236]	_	_
26-5	3682-3691	antiviral	substance[236]	giv[236]	_	_
26-6	3692-3700	molecule	substance[236]	giv[236]	_	_
26-7	3701-3708	against	substance[236]	giv[236]	_	_
26-8	3709-3713	many	substance[236]|animal[237]	giv[236]|giv[237]	_	_
26-9	3714-3721	viruses	substance[236]|animal[237]	giv[236]|giv[237]	_	_
26-10	3722-3723	.	_	_	_	_

#Text=It is the first identified member of the IRF family , but it does not induce production of type I IFNs . Odendall et al has shown that IRF1 regulates peroxisome-mediated IFN-λ1 expression .
27-1	3724-3726	It	abstract	giv	coref	27-3[239_0]
27-2	3727-3729	is	_	_	_	_
27-3	3730-3733	the	abstract[239]	giv[239]	ana	27-13[0_239]
27-4	3734-3739	first	abstract[239]	giv[239]	_	_
27-5	3740-3750	identified	abstract[239]	giv[239]	_	_
27-6	3751-3757	member	abstract[239]	giv[239]	_	_
27-7	3758-3760	of	abstract[239]	giv[239]	_	_
27-8	3761-3764	the	abstract[239]|abstract[241]	giv[239]|new[241]	_	_
27-9	3765-3768	IRF	abstract[239]|person|abstract[241]	giv[239]|new|new[241]	_	_
27-10	3769-3775	family	abstract[239]|abstract[241]	giv[239]|new[241]	_	_
27-11	3776-3777	,	_	_	_	_
27-12	3778-3781	but	_	_	_	_
27-13	3782-3784	it	abstract	giv	coref	27-29
27-14	3785-3789	does	_	_	_	_
27-15	3790-3793	not	_	_	_	_
27-16	3794-3800	induce	_	_	_	_
27-17	3801-3811	production	abstract[243]	giv[243]	coref	30-8[263_243]
27-18	3812-3814	of	abstract[243]	giv[243]	_	_
27-19	3815-3819	type	abstract[243]|abstract	giv[243]|giv	coref	28-1[251_0]
27-20	3820-3821	I	person	giv	ana	30-17
27-21	3822-3826	IFNs	abstract	giv	_	_
27-22	3827-3828	.	_	_	_	_
27-23	3829-3837	Odendall	person	new	_	_
27-24	3838-3840	et	_	_	_	_
27-25	3841-3843	al	_	_	_	_
27-26	3844-3847	has	_	_	_	_
27-27	3848-3853	shown	_	_	_	_
27-28	3854-3858	that	_	_	_	_
27-29	3859-3863	IRF1	abstract	giv	coref	31-11
27-30	3864-3873	regulates	_	_	_	_
27-31	3874-3893	peroxisome-mediated	abstract[250]	giv[250]	_	_
27-32	3894-3900	IFN-λ1	person|abstract[250]	new|giv[250]	_	_
27-33	3901-3911	expression	abstract[250]	giv[250]	_	_
27-34	3912-3913	.	_	_	_	_

#Text=Epithelial cells have preference of producing IFN-λs over IFN-α/β upon viral infection .
28-1	3914-3924	Epithelial	abstract[251]	giv[251]	coref	29-12[260_251]
28-2	3925-3930	cells	abstract[251]	giv[251]	_	_
28-3	3931-3935	have	_	_	_	_
28-4	3936-3946	preference	abstract	new	_	_
28-5	3947-3949	of	_	_	_	_
28-6	3950-3959	producing	_	_	_	_
28-7	3960-3966	IFN-λs	abstract	giv	coref	32-12[288_0]
28-8	3967-3971	over	_	_	_	_
28-9	3972-3979	IFN-α/β	abstract	new	ana	29-1
28-10	3980-3984	upon	_	_	_	_
28-11	3985-3990	viral	object|abstract[256]	giv|giv[256]	_	_
28-12	3991-4000	infection	abstract[256]	giv[256]	_	_
28-13	4001-4002	.	_	_	_	_

#Text=This may be due to relatively higher expression of peroxisomes in epithelial cells .
29-1	4003-4007	This	abstract	giv	_	_
29-2	4008-4011	may	_	_	_	_
29-3	4012-4014	be	_	_	_	_
29-4	4015-4018	due	_	_	_	_
29-5	4019-4021	to	_	_	_	_
29-6	4022-4032	relatively	abstract[258]	new[258]	coref	31-19[277_258]
29-7	4033-4039	higher	abstract[258]	new[258]	_	_
29-8	4040-4050	expression	abstract[258]	new[258]	_	_
29-9	4051-4053	of	abstract[258]	new[258]	_	_
29-10	4054-4065	peroxisomes	abstract[258]|substance[259]	new[258]|new[259]	_	_
29-11	4066-4068	in	abstract[258]|substance[259]	new[258]|new[259]	_	_
29-12	4069-4079	epithelial	abstract[258]|substance[259]|abstract[260]	new[258]|new[259]|giv[260]	coref	30-7[0_260]
29-13	4080-4085	cells	abstract[258]|substance[259]|abstract[260]	new[258]|new[259]|giv[260]	_	_
29-14	4086-4087	.	_	_	_	_

#Text=Peroxisomal MAVS is known to induce type III IFNs , as opposed to induction of type I IFNs via mitochondrial MAVS .
30-1	4088-4099	Peroxisomal	animal[261]	new[261]	_	_
30-2	4100-4104	MAVS	animal[261]	new[261]	_	_
30-3	4105-4107	is	_	_	_	_
30-4	4108-4113	known	_	_	_	_
30-5	4114-4116	to	_	_	_	_
30-6	4117-4123	induce	_	_	_	_
30-7	4124-4128	type	abstract	giv	coref	30-16
30-8	4129-4132	III	abstract[263]	giv[263]	coref	30-18[267_263]
30-9	4133-4137	IFNs	abstract[263]	giv[263]	_	_
30-10	4138-4139	,	_	_	_	_
30-11	4140-4142	as	_	_	_	_
30-12	4143-4150	opposed	_	_	_	_
30-13	4151-4153	to	_	_	_	_
30-14	4154-4163	induction	event[264]	new[264]	_	_
30-15	4164-4166	of	event[264]	new[264]	_	_
30-16	4167-4171	type	event[264]|abstract	new[264]|giv	coref	31-7
30-17	4172-4173	I	person	giv	_	_
30-18	4174-4178	IFNs	abstract[267]	giv[267]	coref	31-8[272_267]
30-19	4179-4182	via	abstract[267]	giv[267]	_	_
30-20	4183-4196	mitochondrial	abstract[267]|abstract|abstract[269]	giv[267]|new|new[269]	_	_
30-21	4197-4201	MAVS	abstract[267]|abstract[269]	giv[267]|new[269]	_	_
30-22	4202-4203	.	_	_	_	_

#Text=To better understand the regulation of type III IFNs by IRF1 , we attempted to regulate levels of IRF1 expression by overexpression or RNA interference in IPEC-J2 cells .
31-1	4204-4206	To	_	_	_	_
31-2	4207-4213	better	_	_	_	_
31-3	4214-4224	understand	_	_	_	_
31-4	4225-4228	the	abstract[270]	new[270]	_	_
31-5	4229-4239	regulation	abstract[270]	new[270]	_	_
31-6	4240-4242	of	abstract[270]	new[270]	_	_
31-7	4243-4247	type	abstract[270]|abstract	new[270]|giv	coref	31-27[282_0]
31-8	4248-4251	III	abstract[272]	giv[272]	coref	32-34[297_272]
31-9	4252-4256	IFNs	abstract[272]	giv[272]	_	_
31-10	4257-4259	by	_	_	_	_
31-11	4260-4264	IRF1	abstract	giv	coref	31-19
31-12	4265-4266	,	_	_	_	_
31-13	4267-4269	we	person	giv	_	_
31-14	4270-4279	attempted	_	_	_	_
31-15	4280-4282	to	_	_	_	_
31-16	4283-4291	regulate	_	_	_	_
31-17	4292-4298	levels	abstract[275]	new[275]	_	_
31-18	4299-4301	of	abstract[275]	new[275]	_	_
31-19	4302-4306	IRF1	abstract[275]|abstract|abstract[277]	new[275]|giv|giv[277]	coref|coref	32-3|32-3
31-20	4307-4317	expression	abstract[275]|abstract[277]	new[275]|giv[277]	_	_
31-21	4318-4320	by	abstract[275]|abstract[277]	new[275]|giv[277]	_	_
31-22	4321-4335	overexpression	abstract[275]|abstract[277]|abstract	new[275]|giv[277]|new	coref	32-1[283_0]
31-23	4336-4338	or	abstract[275]|abstract[277]	new[275]|giv[277]	_	_
31-24	4339-4342	RNA	abstract[275]|abstract[277]|organization|abstract[280]	new[275]|giv[277]|new|new[280]	_	_
31-25	4343-4355	interference	abstract[275]|abstract[277]|abstract[280]	new[275]|giv[277]|new[280]	_	_
31-26	4356-4358	in	abstract[275]|abstract[277]|abstract[280]	new[275]|giv[277]|new[280]	_	_
31-27	4359-4366	IPEC-J2	abstract[275]|abstract[277]|abstract[280]|substance|abstract[282]	new[275]|giv[277]|new[280]|giv|giv[282]	coref|coref	32-33[0_282]|32-33[0_282]
31-28	4367-4372	cells	abstract[275]|abstract[277]|abstract[280]|abstract[282]	new[275]|giv[277]|new[280]|giv[282]	_	_
31-29	4373-4374	.	_	_	_	_

#Text=Overexpression of IRF1 led to a significant increase of transcription of all IFN-λs and IFN-λ3 promoter activity , while gene silencing showed opposite effects , indicating that IRF1 positively regulates expression of type III IFNs .
32-1	4375-4389	Overexpression	abstract[283]	giv[283]	_	_
32-2	4390-4392	of	abstract[283]	giv[283]	_	_
32-3	4393-4397	IRF1	abstract[283]|object	giv[283]|giv	coref	32-28
32-4	4398-4401	led	_	_	_	_
32-5	4402-4404	to	_	_	_	_
32-6	4405-4406	a	abstract[285]	new[285]	_	_
32-7	4407-4418	significant	abstract[285]	new[285]	_	_
32-8	4419-4427	increase	abstract[285]	new[285]	_	_
32-9	4428-4430	of	abstract[285]	new[285]	_	_
32-10	4431-4444	transcription	abstract[285]|abstract[286]	new[285]|new[286]	_	_
32-11	4445-4447	of	abstract[285]|abstract[286]	new[285]|new[286]	_	_
32-12	4448-4451	all	abstract[285]|abstract[286]|abstract[287]|abstract[288]	new[285]|new[286]|new[287]|giv[288]	_	_
32-13	4452-4458	IFN-λs	abstract[285]|abstract[286]|abstract[287]|abstract[288]	new[285]|new[286]|new[287]|giv[288]	_	_
32-14	4459-4462	and	abstract[285]|abstract[286]|abstract[288]	new[285]|new[286]|giv[288]	_	_
32-15	4463-4469	IFN-λ3	abstract[285]|abstract[286]|abstract[288]|place|abstract[291]	new[285]|new[286]|giv[288]|giv|giv[291]	_	_
32-16	4470-4478	promoter	abstract[285]|abstract[286]|abstract[288]|person|abstract[291]	new[285]|new[286]|giv[288]|giv|giv[291]	_	_
32-17	4479-4487	activity	abstract[285]|abstract[286]|abstract[288]|abstract[291]	new[285]|new[286]|giv[288]|giv[291]	_	_
32-18	4488-4489	,	_	_	_	_
32-19	4490-4495	while	_	_	_	_
32-20	4496-4500	gene	abstract	new	_	_
32-21	4501-4510	silencing	_	_	_	_
32-22	4511-4517	showed	_	_	_	_
32-23	4518-4526	opposite	abstract[293]	new[293]	_	_
32-24	4527-4534	effects	abstract[293]	new[293]	_	_
32-25	4535-4536	,	_	_	_	_
32-26	4537-4547	indicating	_	_	_	_
32-27	4548-4552	that	_	_	_	_
32-28	4553-4557	IRF1	abstract	giv	_	_
32-29	4558-4568	positively	_	_	_	_
32-30	4569-4578	regulates	_	_	_	_
32-31	4579-4589	expression	abstract[295]	giv[295]	_	_
32-32	4590-4592	of	abstract[295]	giv[295]	_	_
32-33	4593-4597	type	abstract[295]|abstract	giv[295]|giv	_	_
32-34	4598-4601	III	abstract[297]	giv[297]	_	_
32-35	4602-4606	IFNs	abstract[297]	giv[297]	_	_
32-36	4607-4608	.	_	_	_	_
